

Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte-like cells

Fotios Sampaziotis^{1,2,3}, Miguel Cardoso de Brito^{1*}, Imbisaat Geti^{1*}, Alessandro Bertero^{1*}, Nicholas RF Hannan^{4†}, Ludovic Vallier^{1,2,5†}.

¹Wellcome Trust-Medical Research Council Stem Cell Institute, Cambridge Stem Cell Institute, Anne McLaren Laboratory, Department of Surgery, University of Cambridge, Cambridge, UK

²Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK

³Department of Hepatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁴Center for Biomolecular Sciences, University of Nottingham, UK

⁵Wellcome Trust Sanger Institute, Hinxton, UK

Authorship note: * Miguel Cardoso de Brito, Imbisaat Geti and Alessandro Bertero contributed equally to this manuscript. † Ludovic Vallier and Nicholas RF Hannan share senior authorship for this manuscript.

Correspondence: Ludovic Vallier, Laboratory for Regenerative Medicine, West Forvie Building, Robinson Way, University of Cambridge. Cambridge CB2 0SZ, United Kingdom. Telephone: 44.1223.747489; Fax: 44.1223.763.350; E-mail: lv225@cam.ac.uk

1 **Abstract**

2 The difficulty in isolating and propagating functional primary cholangiocytes is
3 a major limitation in studying biliary disorders and testing novel therapeutic
4 agents. To overcome this problem, we have developed a platform for the
5 differentiation of human Pluripotent Stem Cells (hPSCs) into functional
6 cholangiocyte-like cells (CLCs). We have previously reported that our 26-day
7 protocol closely recapitulates key stages of biliary development starting with
8 the differentiation of hPSCs into endoderm and subsequently foregut
9 progenitor cells, followed by the generation of hepatoblasts, cholangiocyte
10 progenitors expressing early biliary markers and mature CLCs displaying
11 cholangiocyte functionality. Compared to alternative protocols for biliary
12 differentiation of hPSCs, our system does not require co-culture with other cell
13 types and relies on chemically defined conditions up to and including the
14 generation of cholangiocyte progenitors. A complex extracellular matrix is
15 used for the maturation of CLCs, therefore experience in hPSC culture and
16 3D organoid systems may be necessary for optimal results. Finally, the
17 capacity of our platform for generating large amounts of disease-specific
18 functional cholangiocytes will have broad applications for cholangiopathies, in
19 disease modeling and for screening of therapeutic compounds.

20

21

1 INTRODUCTION

2

3 Adult bile ducts consist of highly functional biliary epithelial cells¹ which
4 regulate bile homeostasis and modulate inflammatory responses. These cells
5 are also known as cholangiocytes and represent the main cell type affected in
6 cholangiopathies^{2,3}; a diverse group of liver disorders including diseases such
7 as Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Despite the
8 growing importance of these diseases, research in biliary physiology and the
9 development of new therapeutics have been hampered by the lack of robust
10 platforms for disease modeling and high-throughput drug screening^{3,4}.
11 Although animal models exist, their capacity for fully reproducing human
12 pathophysiology is limited^{5,6}; while access to primary biliary tissue remains
13 problematic prohibiting large scale experiments. Here, we describe a protocol
14 for generating large quantities of CLCs from human hPSCs, which can be
15 applied to model cholangiopathies *in vitro* and validate the effects of
16 therapeutic compounds⁶.

17

18 Development of the protocol

19 The protocol for the generation of cholangiocyte-like cells⁷ was developed by
20 recapitulating key stages of native bile duct development (Figure 1a).
21 Cholangiocytes originate from hepatoblasts (HBs), a bipotent population of
22 embryonic liver progenitor cells⁸, which can also differentiate into
23 hepatocytes. Hepatoblasts surrounding the portal vein give rise to a

1 monolayer of immature cholangiocyte progenitor cells (the ductal plate)⁸,
2 which undergoes a process of 3D remodeling and maturation resulting in
3 functional bile ducts.

4 The generation of bipotent HBs was based on our established methodology
5 for producing hPSC-derived hepatocyte-like cells⁹. To achieve biliary
6 commitment of HBs, we used physiological cues reported to control biliary
7 specification such as Activin-A (a member of the TGFbeta superfamily)^{8,10} and
8 Fibroblast Growth Factor (FGF) 10¹¹. Screening a variety of growth factors,
9 we also identified a requirement for Retinoic Acid⁷. The combined activation of
10 these signaling pathways was sufficient to promote differentiation of HBs to
11 cholangiocyte progenitors expressing early biliary markers including KRT19
12 and SOX9⁷.

13 Maturation of native cholangiocytes happens in synchrony with 3D
14 rearrangement of the ductal plate into tubular structures⁸. Most of the
15 functional properties of the biliary epithelium are associated with absorption
16 and secretion processes, which require a polarized epithelium forming a
17 lumen and therefore cannot be accurately reproduced by cells organized in
18 monolayer^{12,13}. Consequently, for the final stage of our protocol promoting CP
19 maturation to CLCs, we developed a 3D culture system, based on previous
20 studies using matrigel and Epidermal Growth Factor (EGF)^{14,15} which promote
21 spontaneous differentiation of hepatoblasts into cystic structures expressing
22 early biliary markers, such as KRT19^{14,15}. Prolonged culture of CPs under
23 these conditions resulted in CLC organoids with a central lumen
24 demonstrating characteristic functional properties, such as GGT activity⁷

1

2 **Applications**

3 The mechanisms controlling development of the human biliary tree remain
4 poorly understood. Indeed, developmental studies in humans is limited by
5 minimal access to fetal tissue, while animal models fail to fully recapitulate the
6 development of the human biliary tree or the phenotype of developmental
7 disorders⁶. Our *in vitro* system could address some of these challenges, as it
8 relies on a step-wise differentiation protocol which closely mimics embryonic
9 bile duct development. Therefore, significant numbers of cells corresponding
10 to different embryological stages can be easily generated, enabling
11 mechanistic large scale studies in biliary specification or developmental
12 disorders. Accordingly, we applied this methodology to interrogate the role of
13 TGF β and Notch signaling in biliary tubulogenesis and reproduce the
14 phenotype of Alagille Syndrome *in vitro*⁷. The same principle could be used in
15 future studies to explore a broad spectrum of pathways which could be
16 involved in bile duct development and pathogenesis.

17 CLCs also recapitulate many physiological functions of cholangiocytes *in vitro*
18 as well as their defects in the context of disease when using hPSCs derived
19 from patients with cholangiopathies⁷. Consequently, CLCs could present an
20 optimal platform for modeling biliary disease, validating therapeutic
21 compounds and screening for novel treatment agents. We have already
22 demonstrated proof-of-principle for the feasibility of this application by
23 reproducing the effects of the drugs verapamil and octreotide in our culture
24 system⁷ and using patient specific hiPSCs to identify a new application for the

1 experimental compound VX809 in the management of Cystic Fibrosis
2 Cholangiopathy⁷. Importantly, the capacity of our system for generating
3 significant numbers of CLCs⁷ combined with its compatibility with large scale
4 experiment formats (24 and 48 well plates)⁷ could set the foundation for the
5 development of high-throughput drug screening platforms for
6 cholangiopathies in the future using patient-derived CLCs.

7 **Comparison with other methods**

8 Primary cholangiocyte isolation has been reported^{16–18}. However, these
9 methodologies are technically challenging, only support short term growth
10 with limited expansion and generate limited numbers of cells, all of which are
11 not compatible with large scale experiments^{16–18}. Furthermore, primary
12 cholangiocytes cultured in monolayer systems have not been shown to
13 maintain their functional properties^{16–18}.

14 Two other protocols have been described for generating biliary epithelium
15 from hPSCs^{19,20}. The method by Dianat et al. results in cells with a
16 transcriptional signature^{7,20} compatible with a sub-population of
17 cholangiocytes located in the canals of Hering known as small
18 cholangiocytes²¹. Therefore, this approach is optimized for studies on small
19 cholangiocytes and complements our protocol which is aimed towards the
20 production of large cholangiocytes. The method by Ogawa et al. generates
21 cholangiocyte organoids expressing mature markers and demonstrating
22 biliary functionality; however, biliary specification is based in a co-culture
23 system with mouse OP9 cells¹³. Although a mixed culture system may
24 recapitulate more closely the native niche of hepatoblasts/cholangiocytes, it is

1 technically more challenging and presents several limitations. Indeed, OP9
2 cells are derived from bone marrow and are known to promote hematopoietic
3 differentiation of ESCs by secreting factors such as M-CSF. This poses
4 significant limitations for mechanistic studies in biliary specification and early
5 biliary development since unknown secreted factors could interfere with
6 experimental outcomes. Furthermore, the heterogeneity of the cell population
7 in a co-culture system renders –omic studies, such as genome wide analyses
8 more challenging. Consequently, the platform by Ogawa et al may be better
9 suited for studies where accurate reproduction of a complex cellular niche is
10 crucial, while our system is more optimized for mechanistic studies in biliary
11 development and therapeutics.

12

13 **Limitations**

14 There are two main limitations to our platform. Our system relies on a
15 complex extracellular matrix (Matrigel). The composition of Matrigel is not fully
16 defined while variation in the growth factor and protein contents of each batch
17 could affect the efficiency of the final stage of our protocol. Furthermore, the
18 use of matrigel could render the translation of our platform to Good
19 Manufacturing Practice (GMP) conditions challenging and prevent *in vivo*
20 applications towards cell based therapy and regenerative medicine. Another
21 important consideration is the maturity of the generated cells. CLC organoids
22 express both early and mature biliary markers and maintain some fetal
23 characteristics corresponding more accurately to a stage between fetal and
24 fully mature bile ducts. Consequently, prior to modeling adult biliary disorders

1 CLCs should be tested for the presence of the relevant mature markers and
2 functionality.

3

4 **Experimental Design**

5 Our method describes the generation of hPSC-derived CLC organoids over a
6 period of 26 days. Biliary differentiation is achieved through 5 key stages of
7 recapitulating bile duct development (Figure 1). Our protocol starts with the
8 plating of hPSCs on day 0 (d0), while we refer to the first day of differentiation
9 as day 1 (d1). The first stage (d1-3) results in the generation of definitive
10 endoderm (DE) cells. These cells correspond to the common progenitor from
11 which the liver, lung, pancreas, alimentary tract and thyroid arise.
12 Subsequently, DE cells are differentiated into Foregut Progenitor (FP) cells
13 (stage 2, d4-8), which correspond to precursors of the liver, pancreas, lung
14 and thyroid lineages found in the anterior portion of the embryonic alimentary
15 canal. In the third stage (d9-12) FP cells are differentiated to hepatoblasts
16 (HBs), bipotent progenitors of hepatocytes and cholangiocytes, which can
17 give rise to both. The fourth stage (d13-16) results in biliary commitment of
18 HBs and the generation of cholangiocyte progenitors (CPs), which represent
19 early cholangiocytes forming the ductal plate *in vivo*. In the final stage of our
20 method (d17-26) CPs form functional CLC organoids in 3D culture conditions.

21

22 **Starting population considerations** We have demonstrated that this
23 protocol is reproducible with 4 different hPSC lines ⁷ and embryonic stem (ES)
24 cells²² (Figure 2). Variability in differentiation capacity is a common issue with

1 hPSC lines, which may reflect on the efficiency and timing of our protocol.
2 Therefore, some minor optimization steps may be required for each hPSC-line
3 as described in the following sections.

4

5 **Preparation of hPSCs** To achieve high differentiation efficiency the
6 generation of a near homogeneous DE population is crucial. For that hPSCs
7 have to exhibit optimal morphology and minimal background differentiation.
8 They should first be allowed to grow to near confluence (70-80%), then they
9 are broken into small clumps and plated at high density as described in the
10 sections below (Figure 1b; Steps 1-9). Clump size and density plays a critical
11 role in this step. Very small clumps or single cells are not viable after the first
12 day of differentiation, while large clumps differentiate only partially,
13 maintaining the expression of pluripotency markers at their center. Low
14 densities prevent the cells from reaching near confluence by the end of the
15 first stage. This can have a negative impact on paracrine signaling, cell
16 migration and cell to cell contact, which are crucial factors for efficient
17 formation of the foregut epithelium. A minimum of 24 hours is allowed for the
18 hPSCs to adhere to the plate before starting differentiation; however this
19 period can be extended to a maximum of 48 hours if the clump size is thought
20 to be too small.

21

22 **Generation of Definitive Endoderm and Foregut Progenitors** Definitive
23 endoderm differentiation is characterized by morphological changes;
24 epithelial-mesenchymal transition (EMT; Figure 1b); significant proliferation of

the cells and increased death of cells that fail to differentiate. By the end of day 3 the cells should be approaching confluence (Figure 1b) and express Sox17 and EOMES homogeneously (>90%, Figure 3-4). Cell proliferation continues during the FP stage and by the end of day 8 the cells should be forming a confluent epithelium with cells exhibiting a characteristic rhomboidal morphology (Figure 1b). The generation of a near homogeneous population of FP cells is crucial for the efficiency of later stages. Therefore, we recommend that differentiations are optimized to generate cell populations with >95% purity for endoderm and foregut markers (Figure 3-4), such as GATA4 and FOXA2. In particular, for resistant hPSC lines with significant contamination from partially differentiated cells, we recommend splitting the cells at the foregut stage (d6). For lines with lower proliferation rates and good differentiation efficiency this step is optional. If the cells are split at this stage it is very important that they are dissociated to single cells and re-plated at a density allowing the formation of a fully confluent epithelium by d8.

Generation of bipotent hepatoblasts Cell proliferation begins to reduce at this stage, although cells should continue to proliferate at a lower rate. We have noticed variability in proliferation rate between different hPSC lines. Differentiation of FP to HBs should result in a near homogeneous population (>95%) expressing hepatoblast markers (CK19, AFP) (Figure 3-4), which is important for the efficiency of subsequent steps. High cell density of FPs forming a monolayer of relatively small cells is crucial for the success of this stage. For resistant hPSC lines this stage could be prolonged by 24hrs to improve differentiation efficiency. However, significant prolongation of HB

1 differentiation carries the risk of committing a significant proportion of cells to
2 the hepatic lineage which results in increased hepatoblast/ hepatocyte
3 contamination in the next stage and reduced biliary lineage commitment.

4 **Generation of cholangiocyte progenitors** Cell proliferation should increase
5 compared to the previous stage and by the fourth day of cholangiocyte
6 progenitors differentiation significant overgrowth should be seen (100%
7 confluence and/or areas of cells forming multiple layers). Differentiation of
8 HBs to CPs is heterogeneous, resulting in a mixed population of CPs (75%),
9 HBs (15%) and cells at intermediate stages (Figure 4). Consequently, hepatic
10 markers, such as AFP can still be detected, but early biliary markers such as
11 CK19 and SOX9 should also be expressed almost homogeneously (Figure 2,
12 3). Poor efficiency at this stage (<75% SOX9 positive cells) could result in
13 incomplete maturation of CLC organoids in the next step. The quality and
14 duration of the HB stage is critical to limit HB contamination and ensure biliary
15 commitment.

16 Therefore, for resistant hPSC lines we recommend optimizing the duration
17 and efficiency of HB differentiation as described in the previous section
18 (Generation of bipotent hepatoblasts) and in the troubleshooting section
19 (Table 1).

20 **Generation of CLC organoids** For the final stage of our protocol CPs are
21 dissociated into small clumps and transferred to 3D culture conditions.
22 Density and clump size are the most critical factors for the success of this
23 step. Very high densities do not allow adequate space for the cells to expand
24 and re-organize into organoids with a central lumen. Instead, proliferating

1 clumps of cells merge together into large aggregates. Single cells or very
2 small clumps may not be viable, while large clumps gradually migrate and
3 attach to the bottom of the plate forming a monolayer. Consequently, the
4 efficiency of this phase depends on careful manipulation of the quantity of
5 cells, matrigel and media. Minor adjustments to density and clump size may
6 be required for different hPSC lines (see troubleshooting and procedures
7 sections, steps 17-26). For resistant lines such as H9, we recommend adding
8 forskolin (optional step), which promotes intraluminal fluid secretion and
9 facilitates the formation of organoids with a lumen.

10 Of note this step starts with a heterogeneous population of cells including HBs
11 and CPs and thus some hepatic contamination is expected. However, cells
12 expressing hepatic markers, such as AFP fail to form organoids and usually
13 gravitate to the bottom of the plate. On the contrary, by the end of this stage
14 CLC organoids should express biliary (CK19, CK7, SOX9) (Figure 3-4) but not
15 hepatic markers (AFP) and demonstrate functional properties characteristic of
16 biliary epithelium, such as GGT and ALP activity (Figure 5). Importantly, we
17 have noticed differences in differentiation efficiency with different batches of
18 Matrigel. For resistant hPSC lines Matrigel should be screened for batches
19 which support organoid formation and cholangiocyte functionality.

20

21 **Controls**

22 Intrahepatic cholangiocytes are not commercially available. Therefore, we
23 recommend the use of fresh bile duct tissue obtained from liver donors, or

1 frozen isolated common bile duct cholangiocytes commercially available
2 (Celprogen) as a positive control for the expression of biliary markers.

3

4 **MATERIALS**

5

6 **REAGENTS**

7 **CRITICAL** All the reagents listed are reconstituted and stored as per the
8 manufacturer's instructions unless specifically stated

9 hPSCs. All hPSC lines were derived by the Cambridge Biomedical Research
10 Campus (BRC) hPSC core facility (ethics reference no. 08/H0311/201 for
11 Hertfordshire Regional Ethics Committee (REC) and 09/H0304/77 for National
12 Research Ethics Service (NRES) Committee East of England, Cambridge
13 East) **CAUTION** HPSC derivation should always occur in compliance with
14 appropriate national laws and institutional regulations. Informed consent must
15 be obtained from human subjects. **CAUTION** The cell lines used in your
16 research should be regularly checked to ensure they are authentic and are
17 not infected with mycoplasma.

18 Gelatin (Sigma, cat. no. G1890)

19 Water for embryo transfer (Sigma, cat. no. W1503)

20 Advanced DMEM F12 (Life Technologies, cat. no. 12634028)

21 Penicillin-streptomycin (Life Technologies, cat. no. 15140122)

- 1 L-Glutamine (Life Technologies, cat. no. 25030024)
- 2 β -Mercaptoethanol (Sigma, cat. no. M6250) **CAUTION** β -Mercaptoethanol is
3 toxic if ingested, inhaled, or following prolonged skin exposure. Wear
4 protective clothing and use a fume hood.
- 5 FBS (Life Technologies, cat. no. 10500064) **CRITICAL** Due to batch-to-batch
6 variability in serum, serum batches should be screened for their capacity to
7 maintain pluripotency for a minimum of 2 passages. Key features of
8 pluripotent cell growth include characteristic colony morphology, differentiation
9 potential to all 3 germ layers and expression of pluripotency markers such as
10 NANOG, POU5F1 and SOX2.
- 11 Ham's F-12 Nutrient Mix, GlutaMAX™ Supplement (Life Technologies, cat.
12 no. 31765068)
- 13 Iscove's Modified Dulbecco's Medium (IMDM) (Life Technologies, cat. no.
14 21980065)
- 15 Chemically defined lipid concentrate (Life Technologies, cat. no. 11905031)
- 16 Monothioglycerol (Sigma, cat. no. M6145)
- 17 Transferrin (30 mg/ml, Roche, cat. no. 652202)
- 18 Insulin, 10 mg/ml (Roche, cat. no. 1376497)
- 19 Poly(vinyl alcohol) (PVA) 87-90% hydrolyzed (Sigma, cat. no. P8136)
- 20 KnockOut serum replacement (KOSR; Life Technologies, cat. no. 10828028)
- 21 Collagenase IV (Life Technologies, cat. no. 17104019)

- 1 Dispase (Invitrogen, cat. no. 17105041)
- 2 DMEM F-12 (Life Technologies, cat. no. 11330032)
- 3 RPMI 1640 + GlutaMAX (Gibco, cat. no. 61870)
- 4 B-27 supplement containing insulin (Gibco, cat. no. 17504-044) **CRITICAL**
- 5 Due to batch-to-batch variability in B27, B27 batches should be screened for
- 6 their capacity to support HB and CP differentiation in a minimum of 2 different
- 7 differentiation experiments. HB and CP differentiation should be assessed
- 8 based on appropriate markers on flow cytometry analyses. These include
- 9 >95% expression of CK19 and AFP for HBs and >75% expression of Sox9
- 10 and CK19 for CPs (Figure 4).
- 11 MEM non-essential amino acids (MEM-NEAA; Gibco, cat. no. 1140)
- 12 Dulbecco's PBS (DPBS; Life Technologies, cat. no. 14190)
- 13 Cell Dissociation Buffer, enzyme-free, PBS (Gibco, cat. no. 13151014)
- 14 William's E Medium, no phenol Red (Invitrogen, cat. no. A12176-01)
- 15 Dexamethasone (R&D systems, cat. no. 1126/100)
- 16 DMSO (Sigma, cat. no. D2650)
- 17 ITS+ Universal Cell Culture Supplement Premix, 20 ml, 2 L equivalent
- 18 (Corning, cat. no. 354352)
- 19 Nicotinamide (Sigma, cat. no. N0636)
- 20 D-Glucose (Invitrogen, cat. no. 15023021)
- 21 Sodium bicarbonate powder (Sigma, cat. no. S5761)

- 1 2-Phospho-L-Ascorbic Acid Trisodium Salt (Sigma, cat. no. 49752)
- 2 HEPES Solution (Sigma, cat. no. H0887-20ML)
- 3 Sodium Pyruvate (Invitrogen, cat. no. 11360-070)
- 4 Recombinant human Activin A (R&D Systems, cat. no. 338-AC)
- 5 Recombinant human BMP4 (R&D Systems, cat. no. 314-BP)
- 6 Recombinant human FGF basic, 146 aa (R&D Systems, cat. no. 233-FB)
- 7 LY294002 (Promega, cat. no. V1201)
- 8 CHIR99021 (Tocris, cat. no. 4423)
- 9 SB431542 (Tocris bioscience, cat. no. 1614)
- 10 Recombinant Human Keratinocyte Growth Factor-2 (FGF10) (Source
- 11 Bioscience, cat. no. ABC144)
- 12 Retinoic acid (Sigma, cat. no. R2625)
- 13 Y27632 (ROCK Inhibitor) (Selleck, cat. no. S1049)
- 14 Matrigel (BD Biosciences, cat. no. 356237) **CRITICAL** Due to batch-to-batch
- 15 variability in matrigel, matrigel batches should be screened for their capacity
- 16 to support organoid formation and maturation in a minimum of 2 different
- 17 differentiation experiments. Organoids should be clearly identified following 5
- 18 days of culture in matrigel, while small ring structures can be seen as early as
- 19 48-72 hours. CLC maturation should be assessed based on appropriate
- 20 marker expression on flow cytometry analyses and functional assays. These

- 1 include >75% expression of Sox9 and CK7, ALP and GGT activity (Figure 3-
- 2 5).
- 3 Recombinant Human EGF Protein (R&D Systems, cat. no. 236-EG)
- 4 Cell recovery solution (SLS, cat. no. 354253)
- 5 Donkey serum (ab serotec, cat. no. c06sb)
- 6 Triton-X100 solution (Sigma, cat. no. X100-500ML)
- 7 Paraformaldehyde 16% w/v (PFA; Alfa Aesar, cat. no. 30525-89-4)
- 8 GenElute™ Mammalian Total RNA Miniprep Kit (Sigma, cat. no. RTN-350)
- 9 TrypLE™ Express Enzyme (1X), no phenol red (Gibco, cat. no. 12604021)
- 10 Cytokeratin 7 antibody (RCK105) (Abcam, cat. no. ab9021; Table 2)
- 11 Cytokeratin 7 antibody (Abcam, cat. no. ab68459; Table 2)
- 12 Cytokeratin 19 antibody (Abcam, cat. no. ab7754; Table 2)
- 13 SOX9 H-90 antibody (Santa Cruz, cat. no. sc-20095; Table 2)
- 14 TBX3 (A-20) antibody (Santa Cruz, cat. no. sc-17871; Table 2)
- 15 HNF4 (H-171) antibody (Santa Cruz, cat. no. sc-8987; Table 2)
- 16 Alpha fetoprotein (AFP) antibody (DAKO, cat. no. A0008; Table 2)
- 17 Sox17 antibody (R&D, cat. no. AF1924; Table 2)
- 18 TBR2 / Eomes antibody - (Abcam, cat. no. ab23345; Table 2)
- 19 GATA4 (G-4) antibody (Santa Cruz, cat. no. sc-25310; Table 2)

- 1 HNF3b/FoxA2 antibody (R&D, cat. no. AF2400; Table 2)
- 2 Oct-3/4 (H-134) antibody (Santa Cruz, cat. no. sc-9081; Table 2)
- 3 Anti-human NANOG antibody (R&D, cat. no. AF1997; Table 2)
- 4 MaxDiscovery™ gamma-Glutamyl Transferase (GGT) Enzymatic Assay Kit
- 5 (Bioo Scientific, 5601-01)
- 6 BCIP/NBT Color Development Substrate (Promega, S3771)

7

8 **EQUIPMENT**

- 9 CO2 incubator (Sanyo, cat. no. MCO-18AC)
- 10 Centrifuge (Eppendorf, cat. no. 5804)
- 11 Counting chamber (Superior Marienfeld, cat. no. 0640410)
- 12 Disposable serological pipettes, 5 10 and 25 ml (Corning, cat. nos. 4487,
- 13 4488 and 4489)
- 14 Graduated filter tips, 1,000 µl, 200 µl, 20 µl, 10 µl (Starlab, cat. nos. S1122-
- 15 1830, S1120-8810, S1120-1810, S1120-3810)
- 16 Centrifuge tubes, 15 ml and 50 ml (Corning, cat. no. 430791 and 430291)
- 17 500mL Vacuum Filter/Storage Bottle System, 0.22µm Pore (Corning, cat. no.
- 18 431097)
- 19 100mm TC-Treated Culture Dish (Corning, cat. no. 430167)

1 Costar® 12 Well Clear TC-Treated Multiple Well Plates (Corning, cat. no.
2 3513)

3 Costar® 24 Well Clear TC-Treated Multiple Well Plates (Corning, cat. no.
4 3526)

5 Plate heater (TAP Biosystem, cat. no. 016-0R10)

6 Inverted microscope (Olympus, cat. no. CKX41)

7

8 **REAGENT SETUP**

9 **Gelatin for coating tissue culture plates (500 ml)**

10 Dissolve 0.5g of gelatin into 500mls of water for embryo transfer. Heat at 56°C
11 until the gelatin has fully dissolved (approximately 30 minutes). **CRITICAL**
12 Sterilize gelatin solution using a vacuum filter/storage bottle system. Store at
13 room temperature (18–25 °C) for up to 1 month

14 **Serum-containing medium for coating tissue culture plates (500 ml)**

15 Add 50 ml of FBS, 5 ml of glutamine, 5 ml of penicillin-streptomycin
16 (pen/strep) and 3.5 µl of β-mercaptoethanol in 450 ml of Advanced
17 DMEM/F12. **CRITICAL** Sterilize serum-containing medium using a vacuum
18 filter/storage bottle system. Mix well before filtration. Store at 4 °C for up to 1
19 month.

20 **Chemically Defined Medium – PVA (CDM-PVA) medium for maintenance** 21 **of hPSCs**

1 Combine 0.5 g of PVA, 250 ml of F12 + GlutaMAX, 250 ml of IMDM, 5 ml of
2 concentrated lipids, 20 µl of thioglycerol, 350 µl of insulin, 250 µl of transferrin
3 and 5 ml of pen/strep. Store at 4 °C for up to 1 month. Dissolve PVA in IMDM
4 by adding 0.5 g of PVA to 50 ml of IMDM and mixing overnight at 4 °C (e.g.
5 using a 50 ml falcon on a roller). **CRITICAL** Sterilize CDM-PVA medium using
6 a vacuum filter/storage bottle system. Mix well before filtration. Warm to 37 °C
7 before use.

8 **Collagenase, 500 ml**

9 Dissolve 500 mg of Collagenase IV into 400 ml of Advanced DMEM/F12
10 combined with 100 ml of Knockout Serum Replacer, 5 ml of L-Glutamine, 3.5
11 µl of β-Mercaptoethanol. **CRITICAL** Sterilize collagenase using a vacuum
12 filter/storage bottle system. Mix well before filtration. Store at 4 °C for up to 1
13 month. Warm to 37 °C before use.

14 **Dispase, 500 ml**

15 Dissolve 500 mg of Dispase into 500 ml of DMEM F-12. **CRITICAL** Sterilize
16 dispase using a vacuum filter/storage bottle system. Mix well before filtration.
17 Store at 4 °C for up to 1 month. Warm to 37 °C before use.

18 **1:1 Collagenase/Dispase solution for dissociation of hPSCs**

19 Warm collagenase and dispase to 37 °C. Mix 1 volume of collagenase with 1
20 volume of dispase immediately before use. The volumes used are dependent
21 on the number and type of plates used. For each 10 cm plate mix 3 ml of
22 collagenase with 3 ml of dispase.

1 **RPMI/B-27 differentiation medium for the differentiation of FP, HBs and**
2 **CPs (500 ml)**

3 Add 10 ml of B-27, 5 ml of NEAA and 5 ml of pen/strep into 500 ml of RPMI-
4 1640. **CRITICAL** We have noticed variation between different batches of B-
5 27. B-27 batches should be screened for the capacity to support FP, HB and
6 CP differentiation. Appropriate markers for the efficiency of each stage are
7 provided in the experimental design section. Store at 4 °C for a maximum of 3
8 weeks. Warm to 37 °C before use.

9 **Nicotinamide 0.4M stock solution**

10 Dissolve 24.4 g of nicotinamide powder in 500 ml of embryo transfer water.
11 **CRITICAL** Sterilize nicotinamide stock solution using a vacuum filter/storage
12 bottle system. Mix well before filtration. Store at 4 °C for up to 3 months.

13 **Sodium Bicarbonate 1M stock solution preparation**

14 Dissolve 42 g of sodium bicarbonate powder in 500 ml of embryo transfer
15 water. **CRITICAL** Sterilize sodium bicarbonate stock solution using a vacuum
16 filter/storage bottle system. Mix well before filtration. Store at 4°C for up to 3
17 months.

18 **Ascorbic acid trisodium salt 100mM stock solution preparation**

19 Dissolve 16.1 g of Ascorbic acid trisodium salt powder in 500 ml of embryo
20 transfer water. **CRITICAL** Sterilize ascorbic acid trisodium salt stock solution
21 using a vacuum filter/storage bottle system. Mix well before filtration. Store at
22 4 °C for up to 3 months. Protect from light.

1 **D-Glucose 1M stock solution preparation**

2 Dissolve 90.1 g of D-glucose powder in 500 ml of embryo transfer water.
3 Warm to 50°C to facilitate dissolution **CRITICAL** Sterilize D-glucose stock
4 solution using a vacuum filter/storage bottle system. Mix well before filtration.
5 Store at 4 °C for up to 3 months.

6 **Dexamethasone 10 mM stock solution**

7 Dissolve 100 mg of Dexamethasone in 25.4797 ml of DMSO. Aliquot in 50-
8 100 µl aliquots. Store in -80°C for up to 12 months.

9 **Supplemented William's E medium for the maturation of CPs to CLCs in**
10 **3D culture**

11 Combine 443 ml of William's E (WE) medium with 12.5 ml nicotinamide stock
12 solution, 8.5 ml sodium bicarbonate stock solution, 1 ml ascorbic acid
13 trisodium salt stock solution, 7 ml glucose stock solution, 3.15 ml sodium
14 pyruvate, 10 ml HEPES solution, 5 ml ITS+ premix, 5 µl dexamethasone
15 (R&D Systems), 5.3 ml Glutamine and 5 ml pen/strep. **CRITICAL** Sterilize
16 supplemented WE medium using a vacuum filter/storage bottle system. Mix
17 well before filtration. Store at 4°C for up to 1 month. Warm to 37 °C before
18 use.

19 **Matrigel preparation**

20 10 ml matrigel vials should be thawed slowly in an icebox placed at 4°C
21 overnight. Thawed matrigel should be mixed well and then aliquoted in 1 ml
22 aliquots. Aliquoting of matrigel should always happen in a tissue culture hood
23 to avoid bacterial contamination. Matrigel should be kept constantly on ice to

1 avoid solidification. All equipment coming in contact with matrigel should be
2 pre-cooled to 4°C. This includes pipette tips and media for diluting matrigel.
3 Tubes for aliquoting should be kept on ice. Store matrigel aliquots at -20°C or
4 -80°C for up to 3 months. **CRITICAL** Each aliquot should undergo a maximum
5 of 2 freeze thaw cycles. This can be achieved by adjusting aliquot volumes
6 accordingly.

7 **50%(vol/vol) matrigel solution preparation**

8 Add 1 volume of supplemented WE medium to 1 volume of matrigel and mix
9 thoroughly. **CRITICAL** The supplemented WE medium should be pre-cooled
10 to 4°C. **CRITICAL** Both matrigel and the supplemented WE medium should
11 be kept on ice during and after the preparation of the 50% (vol/vol) solution to
12 avoid solidification.

13 To calculate the volume of supplemented WE medium and matrigel that need
14 to be mixed please use the following formula:

15
$$\text{Volume of supplemented WE} = [(\text{number of 24-plate wells}) \times 50 \mu\text{l}] / 2$$

16 The number of wells is multiplied by 50 μl which corresponds to the volume of
17 each dome and divided by 2 to reflect the matrigel-media ratio (50% or 1:1)

18

19 **EQUIPMENT SETUP**

20 **Gelatin/serum-coated tissue culture plates**

21 Add enough gelatin solution to fully cover the surface of the plate. Indicative
22 volumes are 6 ml for a 10 cm plate and 1 ml for each well of a 12-well plate.

1 Coat for a minimum of 30 min at room temperature, then aspirate the gelatin
2 and replace with enough volume of serum-containing medium to fully cover
3 the surface of the plate. Indicative volumes are 6 ml for a 10 cm plate and 1
4 ml for each well of a 12-well plate. Store in an incubator at 37 °C for up to 1
5 week. **CRITICAL** Allow a minimum of 24 hours at 37 °C before using the
6 plate.

7 **Plate heater setup**

8 Clean the plate heater with trigene and 70%(vol/vol) ethanol and place in a
9 tissue culture hood. Set the temperature to 37 °C and place a 24 well plate on
10 the heating surface **CRITICAL** Allow a minimum of 30 minutes for the plate to
11 warm up, prior to plating matrigel with cells. If you are using multiple plates
12 these can be pre-warmed in an incubator for a minimum of 30 minutes with
13 each plate placed on the plate heater immediately before plating.

14

15 **PROCEDURE**

16 **Passaging of hPSCs TIMING 1 d**

17 1 Ensure that hPSC colonies are growing and maintaining their characteristic
18 morphology²³. We recommend using lines which have been stable in culture
19 for at least 10 passages. Change the medium daily using CDM-PVA
20 supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml). Proceed to the
21 next step when the cells are 70-80% confluent.

22 2 Aspirate the medium and wash the plate with Ca²⁺ + /Mg²⁺ + -free PBS. The
23 volume of PBS depends on the type of plate used. Indicative minimum

1 volumes are 6 ml for a 10 cm plate, 1-2 ml for a well of a 6-well plate and 0.5
2 ml for a well of a 12-well plate.

3 3 Aspirate the PBS and add the appropriate volume of 1:1
4 collagenase/dispase solution. Refer to step 2 for indicative volumes. Incubate
5 at 37 °C for 30-60 min until the majority of the colonies (>90%) have
6 detached.

7 4 Tilt the plate and wait for the colonies to gravitate to its lowest part forming a
8 loose pellet. Using a 1000 µl pipette harvest the cells and transfer to a 15 ml
9 tube containing 6 ml of CDM-PVA.

10 5 Allow 1-2 minutes for the colonies to settle to a loose pellet. Aspirate the
11 supernatant and add 6 ml of CDM-PVA. Repeat this step twice for a total of 2
12 washes with CDM-PVA.

13 6 Aspirate the supernatant and re-suspend the pellet in 1 ml of CDM-PVA
14 supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml). **CRITICAL STEP**
15 Using a 1000 µl pipette gently break the colonies into small clumps. Clump
16 size can effect differentiation efficiency. Aim for clumps of 50–100 cells
17 (Figure 1b).

18 7 Prepare new plates by washing gelatin coated plate with PBS as described
19 in step 2. Aspirate the PBS and add the appropriate volume of CDM-PVA
20 supplemented with Activin (10 ng/ml) and bFGF (12 ng/ml) as described in
21 step 2

22 8 Add 100 µl of the cell suspension (step 6) to each 10 cm dish. **CRITICAL**
23 **STEP** hPSCs should be plated in a density that will allow them to reach 80%

1 confluence in 6 – 8 days for maintenance plates and 3-6 days for
2 differentiation (Figure 1b). This is usually achieved by using a 1:6 – 1:10 split
3 ratio. Adjust the volume of cell suspension added to each plate based on your
4 split ratio. Optimal split ratios vary and need to be adjusted for each individual
5 hPSC-line depending on its growth parameters. A typical plating density for
6 our lines is 200,000 cells per 10 cm plate for maintenance and 500,000 –
7 1,000,000 cells for differentiation

8 9 Incubate the cells at 37 °C overnight

9 **Differentiation of hPSCs into definitive endoderm TIMING 3 d**

10 10 *Day 1* Ensure hPSCs have fully attached after plating. Aspirate the
11 medium and add freshly prepared CDM-PVA supplemented with Activin A
12 (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10 µM) and
13 CHIR99021 (3 µM). Incubate the cells at 37 °C overnight

14 **? TROUBLESHOOTING**

15 11 *Day 2* Replace the medium with freshly prepared CDM-PVA supplemented
16 with Activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10
17 µM). Incubate the cells at 37 °C overnight

18 12 *Day 3* Replace the medium with freshly prepared RPMI/B27 medium
19 supplemented with Activin A (100 ng/ml) and bFGF (80 ng/ml). Incubate the
20 cells at 37 °C overnight. The typical morphology of the cells at the end of this
21 stage is demonstrated in figure 1b. A proportion of the cells can be further
22 characterized with flow cytometry and IF for the expression of endoderm
23 markers such as Sox17, anticipating >90% positive cells (Figure 3-4).

1 **? TROUBLESHOOTING**

2 **Differentiation of definitive endoderm into foregut progenitor cells**

3 **TIMING 5 d**

4 13 *Day 4-6* Replace the medium daily with freshly prepared RPMI/B27
5 medium supplemented with Activin A (50 ng/ml).

6 14 *Day 7* Assess the homogeneity and morphology of the cells. The typical
7 morphology of the cells on d7 is demonstrated in figure 1b. If cells exhibit
8 optimal morphology with minimal contamination from undifferentiated or
9 partially differentiated cells, then complete FP differentiation without splitting
10 the cells (option A). For populations with sub-optimal morphological
11 characteristics and significant contamination with poorly differentiated cells or
12 if the cells are overgrown proceed to split the cells (option B).

13 **(A) Completion of FP differentiation without splitting TIMING 2d**

14 (i) *Day 7-8* Replace the medium daily with freshly prepared RPMI/B27
15 medium supplemented with Activin A (50 ng/ml)

16 **? TROUBLESHOOTING**

17 **(B) Splitting cells and completion of FP differentiation TIMING 2d**

18 (i) *Day 7* Prepare new plates as described in step 7

19 (ii) Wash the cells once with PBS as described in step 2. Add the appropriate
20 volume of cell dissociation buffer as described in step 2 and incubate at 37 °C
21 for 20 min until the cells have detached. Tap the plate to facilitate detachment.

1 (iii) Transfer the cells in a 15 ml tube. Gently aspirate and re-suspend the cell
2 solution using a 5 ml serological pipette, to facilitate dissociation to single
3 cells.

4 (iv) Wash the plate that contained the cells with 1 volume of RPMI/B27
5 medium and transfer the wash to the 15 ml tube

6 (v) Centrifuge at 444 *g* for 3 minutes. Aspirate the supernatant and resuspend
7 the cells in 6 ml of RPMI/B27 medium.

8 (vi) Use a counting chamber to count the number of cells in the suspension

9 (vii) Centrifuge at 444 *g* for 3 minutes. Aspirate the supernatant and re-
10 suspend the cells the appropriate volume of freshly prepared RPMI/B27
11 medium supplemented with Activin A (50 ng/ml) and Rho kinase inhibitor Y-
12 27632 (10 μ m) for a final concentration of 1×10^6 cells/ml.

13 **CRITICAL STEP** Y-27632 should always be freshly added and kept in the
14 culture for a minimum of 24 hours to improve cell survival.

15 (viii) Add the appropriate volume of cell suspension to the new plates to
16 provide coverage of 150,000 cells / cm². Ensure this is more than the
17 minimum volume indicated in step 2 and supplement with freshly prepared
18 RPMI/B27 medium supplemented with Activin A (50 ng/ml) if required.

19 (ix) Incubate at 37 °C overnight

20 **CRITICAL STEP** The density of the cells following the split may affect the
21 efficiency of the later steps of differentiation. It is crucial to plate the cells at an
22 appropriately high density so that the cells are almost confluent (90%)

1 following the split. In some cases not all the cells attach therefore it is crucial
2 to look at the plates and if necessary, increase the cell number plated to
3 achieve the right confluence Very high densities promoting growth of cells in
4 overlapping layers also have a negative impact on differentiation efficiency
5 and should be avoided.

6 (x) *Day 8* Replace the medium with freshly prepared RPMI/B27 medium
7 supplemented with Activin A (50 ng/ml). Incubate at 37 °C overnight. Further
8 characterize a proportion of the cells with IF and flow cytometry analyses for
9 the expression of foregut markers such as GATA4 (Figure 3-4), anticipating
10 >90% positive cells.

11 **CRITICAL STEP** The typical morphology of the cells at the end of this stage
12 can be seen in figure 1b.

13 ? TROUBLESHOOTING

14 **Differentiation of foregut progenitor cells into hepatoblasts TIMING 4 d**

15 15 *Day 9-12* Replace the medium daily with freshly prepared RPMI/B27
16 medium supplemented with SB-431542 (10 µM) and BMP-4 (50 ng/ml).
17 Monitor hepatoblast differentiation through the expression of HNF4A, AFP
18 and TBX3 by IF and flow cytometry analyses.

19 **CRITICAL STEP** The typical morphology of the cells is demonstrated in figure
20 1b. Optimal hepatoblast differentiation is necessary for efficient differentiation
21 of later stages. AFP expression should be observed in >95% of the cells by
22 day 12 (Figure 3-4)

23 ? TROUBLESHOOTING

1 **Differentiation of hepatoblasts into cholangiocyte progenitors TIMING**

2 **4d**

3 16 *Day 13-16* Replace the medium daily with freshly prepared RPMI/B27
4 medium supplemented with FGF10 (50 ng/ml), Activin-A (50 ng/ml) and
5 Retinoic acid (3 μ M). Monitor CP differentiation through the expression of Sox9
6 which should be observed in >75% of the cells by day 16 (Figure 4).

7 **CRITICAL STEP** The typical morphology of the cells is demonstrated in figure
8 1b. Optimal CP differentiation is necessary for efficient differentiation of later
9 stages. ? **TROUBLESHOOTING**

10 **Passaging of cholangiocyte progenitors and transfer to 3D culture**
11 **conditions TIMING 1-2h**

12 **CRITICAL** Prior to starting this step ensure that the matrigel and related
13 equipment is prepared as described in the reagent setup section and the plate
14 heater and the required number of plates are prepared as described in the
15 equipment setup section.

16 17 *Day 17* Wash the cells once with PBS and add the appropriate volume of
17 cell dissociation buffer as described in step 2. Incubate at 37 °C for 20 min.

18 18 Tap the plate to facilitate detachment. The cells should detach as a
19 monolayer or large clumps. If no detachment can be identified after 20 min
20 proceed to mechanical dissociation with a pipette using a combination of
21 horizontal, perpendicular and circular movements. We used a 1000 μ l pipette
22 for harvesting cells from 1 well of a 12-well plate.

1 19 Transfer the cells in a 15 ml tube. Gently aspirate and re-suspend the cell
2 solution 2-3 times, using a 1000 µl pipette, to facilitate dissociation to small
3 clumps.

4 **CRITICAL STEP** Clump size is crucial for the efficiency of the following
5 differentiation step and the formation of organoids. Aim for clumps of 10-50
6 cells. Very small clumps and single cells exhibit poor survival, while large
7 clumps gravitate to the bottom of the plate and fail to form organoids.
8 Optimization of clump size may be required between different lines

9 ? TROUBLESHOOTING

10 20 Wash the plate that contained the cells with 1 volume of RPMI/B27
11 medium and transfer the wash to the 15 ml tube Centrifuge at 444 g for 3
12 minutes. Aspirate the supernatant and resuspend the cells in 6 mls of
13 RPMI/B27 medium.

14 21 Centrifuge at 444 g for 3 minutes. Aspirate the supernatant.

15 22 Re-suspend the cells in the appropriate volume of freshly prepared 50%
16 (vol/vol) matrigel supplemented with EGF (20 ng/ml) and Rho kinase inhibitor
17 Y-27632 (10 µM). Mix thoroughly. **CRITICAL STEP** Cholangiocyte progenitors
18 should be plated in a density that will allow the emerging CLC organoids to
19 reach 80% confluence in 10 days. This is usually achieved by using a 1:6 –
20 1:10 split ratio (1 well of a 12-well plate split to 10 wells of a 24-well plate).
21 Optimal split ratios vary and need to be adjusted for each individual hPSC-line
22 depending on its growth parameters and differentiation efficiency. A typical
23 plating density for our lines is $1 - 2 \times 10^5$ cells

1 **CRITICAL STEP** The 50% (vol/vol) matrigel cell suspension should be kept
2 on ice at all times to avoid solidification

3 23 Mix the 50% (vol/vol) matrigel cell suspension thoroughly while keeping on
4 ice. **CRITICAL STEP** Ensure 24 well plates have been placed on a plate
5 heater or an incubator at least 30 min prior to plating, as described in the
6 equipment setup section. Plating of the 50% (vol/vol) matrigel cell suspension
7 should happen with the plate on the plate heater.

8 **24** To form a matrigel dome in one well of a 24 well plate hold the tip of the
9 1000 µl pipette close to the surface of a well and start pipetting 50 µl of the
10 50% (vol/vol) matrigel cell suspension until a small droplet forms. Lower the
11 pipette tip so that the droplet touches the warm plate surface and gently
12 pipette the remainder of 50 µl. **CRITICAL STEP** Ensure that the droplet does
13 not touch the walls of the well, which could lead to collapse of the matrigel
14 dome.

15 25 Allow 1-2 minutes for the 50% (vol/vol) matrigel cell suspension to solidify.
16 This can be assessed by gently tilting the plate. Turn the plate upside down
17 and incubate at 37 °C for 30 min.

18 26 Add enough supplemented WE with EGF (20 ng/ml) and Rho kinase
19 inhibitor Y-27632 (10 µM) to cover the matrigel domes. For 1 well of a 24 well
20 plate we use 1ml of media.

21 **CRITICAL STEP** Y-27632 should always be freshly added and kept in the
22 culture for a minimum of 24 hours to improve cell survival.

23 **? TROUBLESHOOTING**

1 **Differentiation of cholangiocyte progenitors into Cholangiocyte-like Cell**
2 **(CLC) organoids TIMING 10d**

3 27 *Day 17-26* Replace the medium every 2 days daily with freshly prepared
4 supplemented WE medium with EGF (20 ng/ml). Organoids should start
5 forming following 2-4 days of culture. Monitor CLC differentiation can be
6 through the expression of CK7 which should be observed in >75% of the cells
7 by day 26 (Figure 4), positive ALP staining (Figure 5a) and GGT activity
8 (Figure 5b) of CLC organoids.

9 **CRITICAL STEP** The typical morphology of the cells is demonstrated in figure
10 1b and Supplementary Fig. 1.

11 **? TROUBLESHOOTING**

12 **Characterization of CLC organoids**

13 **Immunofluorescence TIMING 2d**

14 **CRITICAL** A matrigel dilution of 50% (vol/vol) or less should be used for the
15 generation of CLC organoids for staining to allow adequate antibody
16 penetration

17 28 *Day 1* Aspirate the culture medium

18 29 Add 1ml of 4% (wt/vol) PFA per well of a 24-well plate, for 20 minutes at
19 room temperature to fix CLC organoids in matrigel

20 30 Aspirate the PFA

21 31 Wash twice with PBS (10 minutes/wash)

1 32 Permeabilize and block for 1 hour with a 10% (vol/vol) donkey serum and
2 0.1% (vol/vol) Triton-X100 solution in PBS at room temperature

3 33 Stain overnight at 4°C with primary antibody diluted in a solution of 1%
4 (vol/vol) donkey serum and 0.1% TritonX-100 in PBS.

5 34 *Day 2* Wash 3 times with PBS (45 mins/wash)

6 35 Stain the CLC organoids for 1 hour at room temperature with secondary
7 antibody raised in donkey and diluted 1:1000 (vol/vol) in a solution of 1%
8 (vol/vol) donkey serum and 0.1% TritonX-100 in PBS.

9 36 Aspirate the secondary antibody

10 37 Add a solution of Hoechst 33258 1:10000 (vol/vol) in PBS for 10 minutes at
11 room temperature

12 38 Wash 3 times with PBS (45 mins/wash).

13 39 Image using a confocal microscope. All IF images (Figure 2-3) were
14 acquired using a Zeiss LSM 700 confocal microscope. Imagej 1.48k software
15 (Wayne Rasband, NIHR, USA, <http://imagej.nih.gov/ij>) was used for image
16 processing such as merging of different channels.

17 ? TROUBLESHOOTING

18 **Extraction of CLCs from matrigel for further analyses TIMING 40min.**

19 40 Aspirate the medium

20 41 Add 500µl/well of a 24-well plate cell recovery solution

- 1 42 Mechanically dissociate the matrigel and CLC organoids by scrapping with
- 2 the tip of a P1000 pipette and transfer to a 15 ml falcon tube.
- 3 43 Incubate the resulting suspension of fragments of matrigel/CLC organoids
- 4 in cell recovery solution for 30 minutes at 4°C
- 5 44 Centrifuge at 444 g, for 4 minutes
- 6 45 Aspirate the supernatant
- 7 46 Wash twice with supplemented WE medium.
- 8 47 Harvest and lyse CLC organoids for RNA extraction using any
- 9 commercially available kit (we used the GenElute™ Mammalian Total RNA
- 10 Miniprep Kit) or dissociate into single cells for flow cytometry following
- 11 incubation with TrypLE for 5 minutes at 37°C.

12

13 **TIMING**

Steps	Description	Timing
1-9	Passaging of hPSCs	1 day
10-12	Differentiation of hPSCs into definitive endoderm	3 days
13-14	Differentiation of definitive endoderm into foregut progenitor cells	5 days
15	Differentiation of foregut progenitor cells into hepatoblasts	4 days
16	Differentiation of hepatoblasts into cholangiocyte progenitors	4 days
17-26	Passaging of cholangiocyte progenitors and transfer to 3D culture conditions	1-2 hrs
27	Differentiation of cholangiocyte progenitors into CLC organoids	10 days
28-39	IF staining of CLC organoids	2 days
40-47	Extraction of cells from matrigel for further analyses	40mins

14

See Table 1 for Troubleshoot guidance

ANTICIPATED RESULTS

We describe a methodology for the differentiation of hPSCs into functional CLC organoids in 26 days . The early stages of our protocol (DE, FP, HB) result in > 90% cells expressing endoderm and then FP markers (Figure 4). However, biliary specification of hepatoblasts results in 75% CK19+/SOX9+ CPs, which mature to a population of 75% CK7+ CLCs during the final step of our differentiation (Figure 4). The resulting CLC organoids should express biliary markers such as CK19 and CK7 in immunofluorescence (IF) analyses (Figure 2-3). Hepatic markers (AFP, Albumin) can still be detected in these stages due to the presence of a contaminating population of hepatic lineage cells, but these should be identified only in clumps of cells without a lumen or attached to the bottom of the plate. Furthermore CLC organoids could be validated further for additional cholangiocyte markers such as CFTR, AE2, Secretin receptor^{7,24} and should demonstrate functional properties such as luminal accumulation of Rhodamine-123, GGT and ALP activity (Figure 5). The methods used to characterize CLC organoids (flow cytometry, immunofluorescence, Rhodamine-123 accumulation, GGT activity and ALP staining) have been described elsewhere ⁷.

Our platform promotes significant cell expansion. Using 3 different hPSC lines, we observed an average yield of >50x10⁶ CLCs per 1x10⁶ hPSCs. Proliferation should be particularly evident during the generation of CLC organoids. 1x10⁵ CPs should give rise to 50-100 CLC organoids with

1 diameters ranging between 100-1000µm. However, variations in terms of the
 2 expansion potential and the differentiation efficiency of our protocol can occur.
 3 This can be attributed to inherent differences between hPSC lines and batch-
 4 to-batch variability for some of the reagents including matrigel. For
 5 reproducible results the use of fresh medium and well-preserved small-
 6 molecule, recombinant protein and matrigel stocks is essential.

7

8 **Table 1 TROUBLESHOOTING**

Step	Problem	Possible reason	Solution
10	Poor attachment of hPSCs	Longer attachment time required	Repeat step 9 incubating the cells for 1 more day before proceeding to step 10
		Colony size too small	Break colonies into slightly bigger clumps which gravitate to the bottom of the plate more easily, facilitating attachment
		Variability between hPSC lines	Add Rho kinase inhibitor Y-27632 in the medium during passaging
		Poor FBS batch	If this problem occurs with more than one line change FBS batch. Screening FBS batches may be required as outlined in the Reagents section
12	Poor endoderm differentiation efficiency	Suboptimal plating of hPSCs for differentiation	Decrease clump size and increase plating density
		Variability between lines with different sensitivity to activin or Wnt signaling	For particularly resistant lines optimize the dose of activin A in steps 10-12 and CHIR in step 10, by monitoring the impact of increased doses in the efficiency of endoderm differentiation
14A, 14B	Poor FP differentiation	Variability between lines	For persistent contamination with poorly

	efficiency		differentiated cells split the cells using step 14B
		Suboptimal plating of cells following split in step 14B	For poor differentiation efficiency following a split optimize cell density ensuring the cells are confluent by the following day
		Reduced activity of growth factors	Check Activin-A activity
			Use growth factors that are within 5 freeze-thaw cycles
		Poor B27 batch	For particularly resistant lines change B27 batch. Screening B27 batches may be required as outlined in the Reagents section
14B	Poor attachment following split	Suboptimal plating of cells following split in step 14B	Increase cell density
			Use a viability dye such as trypan blue when counting the cells to ensure the appropriate number of live cells are plated.
		Poor FBS batch	If this problem occurs with more than one lines change FBS batch. Screening FBS batches may be required as outlined in the Reagents section
15	Poor hepatoblast differentiation	Suboptimal previous steps	Check and optimize the differentiation efficiency to Foregut Progenitors
			Increase plating density in step 14B to ensure the cells are confluent by step 15
		Reduced activity of growth factors	Check SB431542 activity
			Use growth factors that are within 5 freeze-thaw cycles
		Variability between lines with different sensitivity to activin signaling	For particularly resistant lines the dose of SB431542 can be increased
		Poor B27 batch	For particularly resistant lines change B27 batch. Screening B27 batches may be required as outlined in the Reagents section

16	Poor cholangiocyte progenitor differentiation	Variability between lines with increased sensitivity to the previous differentiation stage resulting in hepatic commitment of the generated hepatoblasts	Minimize hepatoblast contamination by optimizing the duration of the previous stage to avoid hepatic commitment of the cells. Aim for the minimum duration that allows upregulation of hepatoblast markers
		Reduced activity of growth factors	Check activin-A and retinoic acid activity
			Increase the dose of Activin-A
			Use growth factors that are within 5 freeze-thaw cycles
		Variability between lines	The differentiation efficiency of hPSC-derived hepatoblasts into cholangiocyte progenitors is dependent on the culture media. Optimization may be required for particularly resistant lines. Advanced DMEM/F12 can replace RPMI/B27 for selected lines.
19	Clump size too small/ single cells following incubation with cell dissociation buffer	Variability between lines	Poor B27 batch
			For particularly resistant lines change B27 batch. Screening B27 batches may be required as outlined in the Reagents section
26	Poor cell survival following transfer to 3D culture	Variability between lines	Reduce the cell dissociation buffer incubation time
			For sensitive lines omit step 18 (incubation with cell dissociation buffer) and proceed to mechanical dissociation only in step 19
			If even mechanical dissociation alone results in single cells/ small clumps check cell density and plate the cells at higher density in step 14B
26	Poor cell survival following transfer to 3D culture	Variability between lines	Optimize clump size. More sensitive lines may require larger clump sizes
			Optimize plating density.

			Low plating densities are associated with poor survival
		Reduced activity of reagents	Check Y-27632 activity and ensure it is freshly prepared
		Increased cell death secondary to vigorous mechanical dissociation	Avoid vigorous mechanical dissociation of the cells during passaging
27	Poor organoid formation and/ or poor CLC differentiation and/ or poor CLC function	Suboptimal previous steps	Check the differentiation efficiency of cholangiocyte progenitors
		Variability between lines	Optimize clump size and plating density.. Aim for smaller clumps and lower density if there is significant attachment of cells to the bottom of the plate
			For resistant lines consider adding forskolin to the culture medium
		Poor matrigel batch	For particularly resistant lines change matrigel batch. Screening matrigel batches may be required as outlined in the Reagents section
39	Unsuccessful staining	Poor antibody penetration	Decrease the matrigel dilution to 40%
			Place the plate on a lab rocker during the staining and washing steps
		Difficulties acquiring optimal images in 3D while CLC organoids are embedded in matrigel	Grow CLC organoids on chamber slides and use alternative staining method; remove chambers and snap freeze or repeat steps 27-37 and use a cover slip to flatten organoids
		Inadequate optimization for antibodies	Optimize antibody concentration, duration of washing and staining steps

1

2 Table 2 ANTIBODY LIST

Target antigen	Supplier	Cat No.	Cell Type	Analyses	Fluorophore type	Clone	Buffer	Concentration	Dilution
SOX17	R&D	AF1924	Endoderm	IF	Unconjugated	Polyclonal	Donkey Serum (DS)	200 µg/ml	1:100
GATA4	Santa Cruz	sc-25310	FP	FC	Unconjugated	G-4	DS	200 µg/ml	1:100
HNF4A	Santa Cruz	sc-8987	HB	IF	Unconjugated	H-171	DS	200 µg/ml	1:100
AFP	Dako	A-008	HB	IF/FC	Unconjugated	Polyclonal	DS	344 000 IU/mL	1:100
TBX3	Santa Cruz	sc-17871	HB	IF	Unconjugated	A-20	DS	200 µg/ml	1:100
SOX9	Santa Cruz	sc-20095	CP/CLCs	IF/FC	Unconjugated	H-90	DS	200 µg/ml	1:100
CK7	Abcam	ab68459	CLC	IF/FC	Unconjugated	EPR1619Y	DS	0.111 mg/ml	1:100
CK7	Abcam	ab9021	CLC	IF/FC	Unconjugated	RCK105	DS	1 mg/ml	1:100
NANOG	R&D	AF1997	hPSCs	IF/FC	Unconjugated	Polyclonal	DS	200 µg/ml	1:100
Oct3-4	Santa Cruz	sc-9081	hPSCs	IF/FC	Unconjugated	H-134	DS	200 µg/ml	1:100
CK19	Abcam	ab7754	CLC	IF/FC	Unconjugated	A53-B/A2	DS	1 mg/ml	1:100
TBR2/EOMES	Abcam	ab23345	DE	IF/FC	Unconjugated	Polyclonal	DS	200 µg/ml	1:100
FOXA2	R&D	AF2400	FP	FC	Unconjugated	Polyclonal	DS	200 µg/ml	1:100

1

2

3 **Author contributions:** FS: Design and concept of study, execution of
4 experiments and data acquisition, development of protocols and validation,
5 collection of data, production of figures, manuscript writing, editing and final
6 approval of manuscript. MCDB, IG, AB: Execution of experiments, collection
7 and provision of data. NRFH: Design and concept of study, editing and final
8 approval of manuscript. LV: Design and concept of study, editing and final
9 approval of manuscript.

10

11 **Acknowledgements:** This work was funded by ERC starting grant Relieve
12 IMDs (L.V., N.H.), the Cambridge Hospitals National Institute for Health

1 Research Biomedical Research Center (L.V., N.H., F.S.), the Evelyn trust
2 (N.H.) and the EU Fp7 grant TissuGEN (M.CDB.). FS has been supported by
3 an Addenbrooke's Charitable Trust Clinical Research Training Fellowship and
4 a joint MRC-Sparks Clinical Research Training Fellowship.

5 The authors would like to thank the Cambridge BRC hiPSCs core facility for
6 the derivation of the Cystic Fibrosis hiPSC line, Dr Paulina Materek for the
7 provision of cells used as negative controls, Dr Daniel Ortmann for his input in
8 the design of the figures and Dr Petroula-Anastasia Tsagkaraki for her help
9 with the generation of the manuscript figures and statistical analyses.

10

11 **Competing financial interests:** LV is a founder and shareholder of
12 DefiniGEN. The remaining authors have nothing to disclose.

13

14

References

1. O'Hara, S. P., Tabibian, J. H., Splinter, P. L. & Larusso, N. F. The dynamic biliary epithelia: Molecules, pathways, and disease. *Journal of Hepatology* **58**, 575–582 (2013).
2. Park, S. M. The crucial role of cholangiocytes in cholangiopathies. *Gut Liver* **6**, 295–304 (2012).
3. Lazaridis, K. N. The Cholangiopathies Konstantinos. *Mayo Clin Proc.* **90**, 791–800 (2015).
4. Sampaziotis, F., Segeritz, C.-P. & Vallier, L. Potential of human induced pluripotent stem cells in studies of liver disease. *Hepatology* **62**, 303–311 (2015).
5. Pollheimer, M. J., Trauner, M. & Fickert, P. Will we ever model PSC? - 'It's hard to be a PSC model!' *Clin. Res. Hepatol. Gastroenterol.* **35**, 792–804 (2011).
6. Lemaigre, F. P. Notch signaling in bile duct development: new insights raise new questions. *Hepatology* **48**, 358–360 (2008).
7. Sampaziotis, F. *et al.* Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. *Nat. Biotechnol.* **33**, 845–852 (2015).
8. Si-Tayeb, K., Lemaigre, F. P. & Duncan, S. A. Organogenesis and Development of the Liver. *Developmental Cell* **18**, 175–189 (2010).

- 1 9. Hannan, N. R. F., Segeritz, C.-P., Touboul, T. & Vallier, L. Production of
2 hepatocyte-like cells from human pluripotent stem cells. *Nat. Protoc.* **8**,
3 430–437 (2013).
- 4 10. Clotman, F. *et al.* Control of liver cell fate decision by a gradient of
5 TGF β signaling modulated by Onecut transcription factors. *Genes*
6 *Dev.* **19**, 1849–1854 (2005).
- 7 11. Yanai, M. *et al.* FGF signaling segregates biliary cell-lineage from chick
8 hepatoblasts cooperatively with BMP4 and ECM components in vitro.
9 *Dev. Dyn.* **237**, 1268–1283 (2008).
- 10 12. Tabibian, J. H., Masyuk, A. I., Masyuk, T. V., O'Hara, S. P. & LaRusso,
11 N. F. Physiology of cholangiocytes. *Compr. Physiol.* **3**, 541–565 (2013).
- 12 13. Ogawa, M. *et al.* Directed differentiation of cholangiocytes from human
13 pluripotent stem cells. *Nat. Biotechnol.* **33**, 853–61 (2015).
- 14 14. Tanimizu, N., Miyajima, A. & Mostov, K. E. Liver Progenitor Cells
15 Develop Cholangiocyte-Type Epithelial Polarity in Three-dimensional
16 Culture. *Mol. Biol. Cell* **18**, 1472–1479 (2007).
- 17 15. Zhao, D. *et al.* Derivation and characterization of hepatic progenitor
18 cells from human embryonic stem cells. *PLoS One* **4**, e6468 (2009).
- 19 16. Tabibian, J. H. *et al.* Characterization of cultured cholangiocytes
20 isolated from livers of patients with primary sclerosing cholangitis. *Lab.*
21 *Invest.* **0**, 1–8 (2014).
- 22 17. Grant, A. G. & Billing, B. H. The isolation and characterization of a bile

- 1 ductule cell population from normal and bile-duct ligated rat livers. *Br J*
2 *Exp Pathol* **58**, 301–10 (1977).
- 3 18. Joplin, R., Strain, A. J. & Neuberger, J. M. Immuno-isolation and culture
4 of biliary epithelial cells from normal human liver. *In Vitro Cell. Dev. Biol.*
5 **25**, 1189–92 (1989).
- 6 19. Zaret, K. S. *et al.* Directed differentiation of cholangiocytes from human
7 pluripotent stem cells. *Eur. J. Cell Biol.* **33**, 1–48 (2015).
- 8 20. Dianat, N. *et al.* Generation of functional cholangiocyte-like cells from
9 human pluripotent stem cells and HepaRG cells. *Hepatology* **60**, 700–
10 14 (2014).
- 11 21. Glaser, S. *et al.* Heterogeneity of the intrahepatic biliary epithelium.
12 *World Journal of Gastroenterology* **12**, 3523–3536 (2006).
- 13 22. Bertero, A. *et al.* Optimized inducible shRNA and CRISPR/Cas9
14 platforms for in vitro studies of human development using hPSCs.
15 *Development* **143**, (2016).
- 16 23. Kent, L. Culture and maintenance of human embryonic stem cells. *J.*
17 *Vis. Exp.* 2–5 (2009). doi:10.3791/1427
- 18 24. Hannan, N. R. F., Sampaziotis, F., Segeritz, C.-P., Hanley, N. A. &
19 Vallier, L. Generation of Distal Airway Epithelium from Multipotent
20 Human Foregut Stem Cells. *Stem Cells Dev.* **24**, 1680–90 (2015).
- 21 25. Agudo, J. *et al.* GFP-specific CD8 T cells enable targeted cell depletion
22 and visualization of T-cell interactions. *Nat. Biotechnol.* **33**, 1287–1292

1 (2015).

2

3

1 **Figure legends**

2 **Figure 1** Generation of Cholangiocyte-like Cells (CLCs) from human
3 Pluripotent Stem Cells (hPSCs). **(a)** Schematic representation of the protocol
4 for the generation of hPSC-derived CLCs. DE: Definitive Endoderm, FP:
5 Foregut progenitors, HB: Hepatoblasts, CP: Cholangiocyte Progenitors; BMP,
6 bone morphogenetic protein; Ly294002 is a phosphatidylinositol-3-OH kinase
7 inhibitor; CDM, chemically defined medium; RPMI, Roswell Park Memorial
8 Institute medium; SB, SB-431542; HGF, hepatocyte growth factor; RA,
9 retinoic acid; EGF, epidermal growth factor; FGF, fibroblast growth factor.
10 Schematic modified from ⁷. The procedure steps corresponding to each stage
11 are noted for reference. **(b)** Light microscopy images of cells at key stages of
12 CLC differentiation. Scale bars for hPSCs, DE, FPs, CPs: 500 µm; HBs: 100
13 µm; zoomed in images: 50µm. The procedure steps and day numbers
14 corresponding to each image are noted for reference.

15

16 **Figure 2** Derivation of CLCs from embryonic stem (ES) cells. IF analyses
17 demonstrating the expression of key biliary markers (CK7, CK19) in a CLC
18 organoid generated from ES cells (H9). Scale bars: 100 µm. See table 2 for a
19 detailed list of the antibodies and concentrations used.

20

21 **Figure 3** Immunofluorescence analyses demonstrating the expression of
22 characteristic markers at key stages of CLC differentiation. Scale bars: 100
23 µm. See table 2 for a detailed list of the antibodies and concentrations used

1 The method for staining CLC organoids is described in procedure steps 28-
2 39.

3

4 **Figure 4** Flow cytometry analyses demonstrating the expression of
5 characteristic markers at key stages of CLC differentiation. CLC organoids
6 were harvested as described in procedure steps 40-47. Cells were
7 dissociated into single cells following incubation with TrypLE for 5 minutes at
8 37°C and fixed with 4% PFA for 20 minutes at 4°C. The cells were stained for
9 IF as previously described⁷, using the antibodies provided in table 2. A
10 standard gating strategy was used²⁵ demonstrated in Supplementary Fig 2. A
11 minimum of 2×10^4 gated events were used for analysis. Post sort fractions are
12 indicated in the quadrants of each graph. The average differentiation
13 efficiency from hPSCs to CLCs across three lines (CK7+/Sox9+ organoids)
14 was 77% (s.d. = 6.5%)⁷.

15

16 **Figure 5** Functional properties of CLC organoids. **(a)** CLC organoids
17 demonstrating characteristic ALP staining. Mouse embryonic feeders are
18 used as a negative control. Scale bars: 100 μ m. **(b)** GGT activity of CLC
19 organoids measured in absorbance units (AU); n=3; Mouse Embryonic
20 Feeders (MEFs) are used as a negative control. Error bars, standard
21 deviation; individual data points are demonstrated; * $P < 0.05$, two tailed
22 student's t-test; F-test used to compare variances, $P = 0.1218$ (no significant
23 difference in variance). GGT and ALP activity were assessed using
24 commercially available kits (MaxDiscovery™ gamma-Glutamyl Transferase

1 (GGT) Enzymatic Assay Kit and BCIP/NBT Color Development Substrate
2 respectively) according to the manufacturer's instructions.

3

4 **Supplementary Figure legends**

5 **Supplementary Figure 1**



6 Morphology of CLC organoids. CLC organoids exhibit a typical cystic or
7 branching tubular morphology. The black arrow indicates a tubular organoid,
8 while the white arrow indicates a branching point. Scale bars: 100µm


9


10 **Supplementary Figure 2**

11 Gating strategy used for the flow cytometry analyses demonstrated in Figure
12 4. Viable cells were gated based on forward scatter and side scatter and
13 single cells were then gated based of forward scatter and pulse width. 2ary
14 only controls were used to set the threshold for the FITC and APC channels.


15







Sampaziotis et al. Figure 4



Sampaziotis et al. Figure 5

